Study of Adjunct Intra-Arterial Thrombolysis After Successful Reperfusion in Acute Stroke of the Anterior Circulation
A Phase 3 Multicenter Randomized Trial Evaluating Alteplase Treatment Outcomes
Led by Central Hospital, Nancy, France · Updated on 2025-06-05
626
Participants Needed
1
Research Sites
41 weeks
Total Duration
AI-Summary
What This Trial Is About
Stroke is a major cause of disability and death worldwide, especially in cases of acute ischemic stroke with large vessel blockage in the brains anterior circulation. This clinical trial is evaluating the use of adjunct intra-arterial thrombolysis versus no adjunct treatment after successful reperfusion by mechanical thrombectomy or other reperfusion therapies. The goal is to see if adding intra-arterial thrombolysis improves functional recovery 90 days after stroke.
The study is a phase 3, randomized, open-label trial comparing two groups one group receives intra-arterial thrombolysis with Alteplase at a dose of 0.225 mgkg maximum 20 mg injected over 15 minutes through a catheter, while the control group receives no additional intra-arterial thrombolysis after standard reperfusion treatments. Patients included have had successful angiographic reperfusion eTICI 2b-2c-3 following intravenous thrombolysis alone, bridging therapy, or mechanical thrombectomy.
Participants will be assessed over 90 days with functional outcome measured by the modified Rankin Scale, and safety monitored within 24 hours of treatment. The trial also includes evaluation of cost-effectiveness and budget impact over 12 months. Follow-up involves neurologic evaluations, imaging confirmation, and clinical visits to monitor recovery and any adverse effects. The total participation period includes baseline treatment and assessments up to 90 days, with longer-term economic evaluations.
CONDITIONS
Brief Title
Intra-Arterial Thrombolysis After SUCCESSful Reperfusion in Anterior Circulation Ischemic Stroke
Research Team
B
Benjamin GORY, MD, PHD
G
Guillaume TURC, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Pre-stroke modified Rankin Scale (mRS) score 0 to 2
Acute ischemic stroke with anterior circulation large vessel occlusion (intracranial internal carotid artery, M1, or M2) confirmed by CT or MRI
NIH Stroke Scale (NIHSS) score of 5 or greater at admission
Acute reperfusion treatment started within 24 hours of stroke onset
DWI-ASPECTS score 2 or greater (MRI) or CT-ASPECTS score 3 or greater
Imaging to puncture time within 3 hours for transferred patients
Successful angiographic reperfusion (eTICI 2b-2c-3) after intravenous thrombolysis alone, bridging therapy, or mechanical thrombectomy
Affiliated with or beneficiary of a social security plan
You will not qualify if you...
Does not speak French
Contraindications to intra-arterial thrombolysis such as platelet count below 100,000/mm3, INR above 1.7, recent use of oral anticoagulants within 48 hours, or active heparin treatment
Bleeding complications after a fall related to stroke
Use of more than 5 thrombectomy devices
Intracerebral hemorrhage
Occlusion or severe narrowing treated by stenting
Expected inability to attend 3-month follow-up visit
Participation in another clinical trial within 30 days that may affect 90-day functional outcome
Women of childbearing age without effective contraception
Persons excluded by specific French Public Health Code articles L.1121-5, L.1121-7, and L.1121-8
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Single administration during acute stroke care
Participants receive intra-arterial thrombolysis with Alteplase or no adjunct intra-arterial thrombolysis after successful reperfusion following intravenous thrombolysis, bridging therapy, or mechanical thrombectomy.
1 treatment visit (in-person)
Follow-up
Duration - Up to 12 months
Participants are monitored for safety and functional outcomes after treatment, including assessment of clinical efficacy and health economics up to 12 months.
Follow-up visits at approximately 24 hours, 90 days, and up to 12 months
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Global Trial Comparing Intra-arterial Thrombolysis with Tenecteplase or Alteplase Versus No Thrombolysis After Endovascular Thrombectomy for Acute Ischemic Stroke
Study of Early Endovascular Treatment for Acute Ischemic Stroke Caused by Isolated Internal Carotid Artery Occlusion
Study of Mechanical Clot Removal Plus Medical Treatment Versus Medical Treatment Alone for Large Stroke with Big Brain Damage
Studying the Impact of Mechanical Thrombectomy on Patient Outcomes at a Small Stroke Center in Norway
Immediate Angioplasty With or Without Stenting for Acute Ischemic Stroke Caused by Severe Intracranial Artery Narrowing A Multicenter Randomized Trial
Evaluating Low-Dose Intra-Arterial Alteplase After Successful Endovascular Thrombectomy for Acute Ischemic Stroke Due to Large Vessel Occlusion
Study of Adjunct Intra-Arterial Thrombolysis After Successful Reperfusion in Acute Stroke of the Anterior Circulation
A Phase 3 Multicenter Randomized Trial Evaluating Alteplase Treatment Outcomes
Urgent Stenting Versus Continued Endovascular Treatment for Stroke Caused by Intracranial Atherosclerosis in Large Vessel Blockage
An International, Multicenter, Randomized Clinical Trial
Comparing Intravenous rhTNK-tPA and Placebo Before Endovascular Thrombectomy for Adults with Large Vessel Occlusion Stroke in an Extended Treatment Window
Evaluating the Efficacy and Safety of MLC901 NeuroAiD II in Mild to Moderate Ischemic Stroke Patients A Randomized Controlled Study
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Intra-Arterial thrombolysis after SUCCESSful angiographic recanalization in acute large-vessel occlusion stroke of the anterior circulation (IA-SUCCESS): a multicentre, randomised, clinical trial protocol.